

# Immuno-Oncology: A Renaissance in the Treatment of Lung Cancer

Saturday, 6 May 2017  
18:40 – 19:40

Scientific Symposium  
Sponsored by MSD

Palexpo  
Room C  
Geneva, Switzerland

Chair: David Carbone (USA)

## CHAIR

**David Carbone**

Barbara J. Bonner Chair in Lung Cancer Research  
President, International Association for the Study of Lung Cancer (IASLC)  
Professor of Medicine  
Director, James Thoracic Oncology Center  
Columbus, Ohio, USA

## FACULTY

**Martin Reck**

Head of the Department of Thoracic Oncology  
Head of the Clinical Trial Department  
Department of Thoracic Oncology  
Lung Clinic Grosshansdorf  
Grosshansdorf, Germany

**Naiyer A. Rizvi**

Professor of Medicine  
Director of Thoracic Oncology and Phase I Immunotherapeutics  
Columbia University Medical Center  
New York, New York, USA

## Educational Objectives

- Establish an understanding of the mechanism of disease in lung cancer and the rationale for checkpoint inhibitors as a treatment option
- Share the experience on the use of immunotherapy in cancer and the unique response patterns associated with treatment in lung cancer
- Educate on biomarkers and their role in guiding treatment decisions

## AGENDA

18:40	Welcome	David Carbone
18:40 – 18:55	Immunotherapy Experience in Lung Cancer	Naiyer Rizvi
18:55 – 19:10	The Value of Biomarkers in Lung Cancer	Martin Reck
19:10 – 19:25	Lung Cancer Landscape: Future Directions	David Carbone
19:25 – 19:40	Panel Discussion	Faculty
19:40	Closing Remarks	David Carbone